New vaccine aims to stop breast cancer recurrence in High-Risk patients
NCT ID NCT02063724
First seen Nov 18, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This early-phase trial tested a personalized vaccine made from a patient's own immune cells, designed to recognize and attack HER-2 positive breast cancer cells. The goal was to see if the vaccine is safe and can boost the immune system to prevent the cancer from returning. The study included 15 women with high-risk or recurrent breast cancer who had completed standard treatments and had no current signs of disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.